Concurrent amplifications and mutations in PIK3CA have previously been reported in uterine serous carcinoma [15], in uterine corpus endometriod cancer (9 of 17 amplified, 53%), head and neck squamous carcinoma (15 of 60 amplified, 25%), lung squamous carcinoma (10 of 67 amplified, 15%), and breast cancer (16 of 37 amplified, 43%) [16],[17]. This evidence concerns the gene PIK3CA and endometrial serous adenocarcinoma.